# HCPCS J0638: Injection, canakinumab, 1mg

Medicare HCPCS J0638 has a Medicare Part B payment limit of $156.95 per 1 MG under 2026 Q4 Medicare Part B drug (ASP) pricing, the same in every state.

Web page: https://www.med-reveal.com/rates/J0638-hcpcs-fee-schedule
Section: Drugs and Biologicals

## Medicare rates

| | Amount |
| --- | --- |
| National non-facility | $156.95 |
| National facility | $156.95 |
| Release | 2026 Q4 (effective 2026-10-01) |

## Related codes

- J0517: Injection, benralizumab, 1mg — https://www.med-reveal.com/rates/J0517-hcpcs-fee-schedule
- J0717: Injection, certolizumab pegol, 1mg — https://www.med-reveal.com/rates/J0717-hcpcs-fee-schedule
- J1602: Injection, golimumab, 1mg — https://www.med-reveal.com/rates/J1602-hcpcs-fee-schedule
- J2182: Injection, mepolizumab, 1mg — https://www.med-reveal.com/rates/J2182-hcpcs-fee-schedule
- J2503: Injection, pegaptanib sodium, 0.3mg — https://www.med-reveal.com/rates/J2503-hcpcs-fee-schedule
- J3262: Injection, tocilizumab, 1mg — https://www.med-reveal.com/rates/J3262-hcpcs-fee-schedule
- J3380: Injection, vedolizumab, 1mg — https://www.med-reveal.com/rates/J3380-hcpcs-fee-schedule
- J9227: Injection, isatuximab-irfc, 10mg — https://www.med-reveal.com/rates/J9227-hcpcs-fee-schedule

Commercial negotiated rates for J0638 by payer and state: https://www.med-reveal.com/solutions/rate-benchmarking

## Sources

- CMS Medicare fee schedules (2026 Q4): https://www.cms.gov/medicare/payment/fee-schedules